|Day's Range||123.13 - 123.90|
|52 Week Range||109.32 - 129.00|
|PE Ratio (TTM)||20.75|
|Earnings Date||Jul 18, 2017|
|Dividend & Yield||3.20 (2.59%)|
|1y Target Est||128.82|
Amgen's top-selling anti-inflammatory drug, Enbrel, may have already hit its high-water mark.
French drugmaker Sanofi said 1Q net profit jumped to about $6.2 billion, boosted by the sale of its animal-health business. To revive growth, Sanofi has boosted its research and is seeking to acquire an ...
NEW DELHI/MUMBAI (Reuters) - A group of global medical-technology companies plans to tell Indian officials next month that any further price control measures would risk future investments and make them less likely to introduce new products in the country, according to an industry source familiar with the matter. The lobbying effort by Abbott Laboratories, Boston Scientific, Johnson & Johnson and others comes after the government of Prime Minister Narendra Modi in February set a price cap for stents - small wire-mesh structures used to treat blocked arteries - slashing prices that patients pay for some devices by about 75 percent.